Analyst Reco. BridgeBio Pharma, Inc.

Equities

BBIO

US10806X1028

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
24.33 ^USD	-2.80%		-2.48%	-39.73%

Apr. 07	BridgeBio Pharma, Inc. Presents Cardiac Magnetic Resonance Imaging Evidence Consistent with Clinical Improvement	CI
Mar. 20	JPMorgan Raises BridgeBio Pharma Price Target to $45 From $35, Maintains Overweight Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JPMorgan Raises BridgeBio Pharma Price Target to $45 From $35, Maintains Overweight Rating	Mar. 20	MT
Cantor Fitzgerald Adjusts Price Target on BridgeBio Pharma to $70 From $60, Maintains Overweight Rating	Mar. 19	MT
Cantor Fitzgerald Adjusts Price Target on BridgeBio Pharma to $60 From $50, Maintains Overweight Rating	Mar. 11	MT
Mizuho Securities Trims Price Target on BridgeBio Pharma to $53 From $60, Keeps Buy Rating	Mar. 04	MT
Citigroup Adjusts BridgeBio Pharma Price Target to $46 From $42, Maintains Buy Rating	Feb. 23	MT
Citigroup Adjusts Price Target on BridgeBio Pharma to $46 From $42, Keeps Buy Rating	Feb. 23	MT
HC Wainwright Raises BridgeBio Pharma Price Target to $47 From $22, Maintains Buy Rating	Jan. 29	MT
JPMorgan Adjusts BridgeBio Pharma Price Target to $35 From $38, Maintains Overweight Rating	Nov. 24	MT
Citigroup Starts BridgeBio Pharma With Buy Rating, $42 Price Target	Nov. 07	MT
BridgeBio Pharma Says Heart Disease Drug Showed 81% Survival Rate in Phase 3 Study	23-08-28	MT
JPMorgan Adjusts Price Target on BridgeBio Pharma to $38 From $42, Maintains Overweight Rating	23-08-17	MT
Mizuho Adjusts Price Target on BridgeBio Pharma to $60 From $50, Maintains Buy Rating	23-08-14	MT
Raymond James Raises Price Target on BridgeBio Pharma to $46 From $29, Maintains Outperform Rating	23-07-18	MT
Goldman Sachs Adjusts Price Target on BridgeBio Pharma to $50 From $29, Maintains Buy Rating	23-07-18	MT
Jefferies Downgrades BridgeBio Pharma to Hold From Buy, Adjusts Price Target to $33 From $24	23-07-18	MT
Mizuho Hikes Price Target on BridgeBio Pharma to $50 From $29, Maintains Buy Rating	23-07-18	MT
In wait-and-see mode before Tesla and Netflix	23-07-17
Mizuho Securities Adjusts BridgeBio Pharma Price Target to $29 From $23, Maintains Buy Rating	23-05-08	MT
Evercore ISI Starts BridgeBio Pharma at Outperform With $40 Price Target	23-04-19	MT
SVB Securities Raises Price Target on BridgeBio Pharma to $27 From $25, Keeps Outperform Rating	23-04-13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. BridgeBio Pharma, Inc.

Equities

BBIO

US10806X1028

Analyst Reco.

Filters